<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3453">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381575</url>
  </required_header>
  <id_info>
    <org_study_id>114700</org_study_id>
    <nct_id>NCT01381575</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls</brief_title>
  <official_title>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine When Administered According to Alternative 2-dose Schedules in 9 - 14 Year Old Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Thailand: Institutional Review Board, Faculty of Medicine, Chulalongkorn University</authority>
    <authority>Taiwan: Food and Drug Administration, Department of Health, Executive Yuan</authority>
    <authority>Canada: Health Canada, Health Products and Food Branch, Biologics and Genetic Therapies Directorate</authority>
    <authority>Thailand: Research Ethics committee, Faculty of Medicine, Chiang Mai University</authority>
    <authority>Italy: A.I.F.A.: Agenzia Italiana del Farmaco (Italian Agency for Medicines)</authority>
    <authority>Germany: Paul Ehrlich Institute</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to evaluate the immunogenicity and safety of GSK Biologicals'
      HPV-16/18 vaccine when administered according to alternative 2-dose schedules (0,6 months
      and 0,12 months) in healthy 9-14 year old females as compared to the standard 3-dose
      schedule (0,1,6 months) in 15-25 year old females.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti- Human Papilloma Virus 16 (Anti-HPV-16) and Anti-Human Papilloma Virus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>1 month after the last dose of study vaccine (Month 7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 ELISA units per millilitre (EL.U/mL) and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</measure>
    <time_frame>1 month after the last dose of study vaccine (Month 7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody concentrations were and expressed as geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay [ELISA] units per millilitre (EL.U/mL), with the cut-off values of 8 EL.U/mL for HPV-016 and 7 EL.U/mL for HPV-018.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 EL.U/mL and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL.
Note: Results for Months 18, 24 and 36 will be updated when they become available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 EL.U/mL and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL. Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16 and Anti-HPV-18 Antibody Titres (by Pseudovirion-Based Neutralisation Assay [PBNA])</measure>
    <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were given as Geometric mean titers (GMTs). The cut-off of the assay were ≥ 40 ED50 for anti-HPV-16 and anti-HPV-18.
Note: Results for Months 24 and 36 will be updated when they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</measure>
    <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody concentrations were expressed as geometric mean titers (GMTs) and given in EL.U/mL, with the cut-off values of ≥ 8 ELISA units per millilitre (EL.U/mL) for HPV-016 and ≥ 7 EL.U/mL for HPV-018Note: Results for Months 18, 24 and 36 will be updated when they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</measure>
    <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody concentrations were expressed as geometric mean titers (GMTs) and given in EL.U/mL, with the cut-off values of ≥ 8 ELISA units per millilitre (EL.U/mL) for HPV-16 and ≥ 7 EL.U/mL for HPV-18.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day period (Days 0-6) following any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited local symptoms were pain, redness and swelling. Any = Occurrence of any solicited local symptom regardless of their intensity grade. Grade 3 pain = Significant pain at rest, that prevented normal every day activity. Grade 3 redness/swelling = Redness/swelling above 50 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During the 7-day period (Days 0-6) following any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, fever and urticaria. Any = Occurrence of any solicited general symptom regardless of intensity grade or relationship to vaccination. Any Fever = Axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C). Grade 3 symptom = Symptom that prevented normal activity. Grade 3 fever = Fever &gt; 39.0 °C. Related = General symptom assessed by the investigator as causally related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 30-day (Days 0-29) post vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 = Unsolicited AE preventing normal activity. Related = Unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)</measure>
    <time_frame>From Day 0 up to Months 7, 13, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>pIMDs are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Note: Results up to Months 24 and 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically Significant Conditions (MSCs)</measure>
    <time_frame>From Day 0 to Months 7, 13, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>MSC include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.
Note: Results up to Months 24 and 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pregnancies Ongoing and Their Outcome</measure>
    <time_frame>From Day 0 up to Months 7, 13, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specific pregnancy outcomes were elective termination with apparent congenital anomaly and ectopic pregnancy. Note: Results for the subsequent timepoints up to Month 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 up to Months 7, 13, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Note: Results up to Month 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific T Cell-mediated Immune Response (CMI)</measure>
    <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The CMI response was the measure of the cytokines production [IL-2, IFN-γ, TNF-α and CD40L] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-18. The frequency was presented as number of cytokine-producing CD4+/CD8+ cells per million CD4+/CD8+ cells.
All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titer lower than the cut-off value of 7 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titer ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific T Cell-mediated Immune Response (CMI)</measure>
    <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The CMI response was the measure of the cytokines production [i.e.interleukin-2 (IL-2), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and cluster of differentiation 40 Ligand (CD40L)] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-16 The frequency was presented as number of of cytokine-positive cluster of differentiation (CD)4 i.e.CD4+/CD8+ cells per million CD4+/CD8+ cells.
All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 8 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 8 El.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific T Cell-mediated Immune Response (CMI)</measure>
    <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The CMI response was the measure of the cytokines production [i.e.interleukin-2 (IL-2), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and cluster of differentiation 40 Ligand (CD40L)] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-16 The frequency was presented as number of of cytokine-positive cluster of differentiation (CD)4 i.e.CD4+/CD8+ cells per million CD4+/CD8+ cells. All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 8 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 8 El.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific T Cell-mediated Immune Response (CMI)</measure>
    <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The CMI response was the measure of the cytokines production [IL-2, IFN-γ, TNF-α and CD40L] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-18. The frequency was presented as number of cytokine-producing CD4+/CD8+ cells per million CD4+/CD8+ cells. All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 7 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific B Cell-mediated Immune Response</measure>
    <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-16 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 8 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 8 EL.U/mL) prior to vaccination.
Note:Results for Months 24 and 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific B Cell-mediated Immune Response</measure>
    <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-18 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 7 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific B Cell-mediated Immune Response</measure>
    <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-16 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 8 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 8 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific B Cell-mediated Immune Response</measure>
    <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-18 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 7 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Completing the Vaccination Course</measure>
    <time_frame>Up to Month 13</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of subjects completing the vaccination course was assessed as the number of subjects with at least one dose received during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16 and Anti-HPV-18 Antibody Titres (by Pseudovirion-Based Neutralisation Assay [PBNA])</measure>
    <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were given as Geometric mean titers (GMTs). The cut-off of the assay were ≥ 40 ED50 for anti-HPV-16 and anti-HPV-18.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1447</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' HPV vaccine 580299</intervention_name>
    <description>Subjects will receive 2 or 3 doses of HPV vaccine administered intramuscularly</description>
    <arm_group_label>Cervarix 3 Group</arm_group_label>
    <arm_group_label>Cervarix 1 Group</arm_group_label>
    <arm_group_label>Cervarix 2 Group</arm_group_label>
    <other_name>Cervarix™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol or/ and subjects who the investigator believes their parent(s)/Legally
             Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of
             the protocol

          -  A female between, and including, 9 and 25 years of age at the time of the first
             vaccination

          -  Written informed consent obtained from the subject/from the parent(s)/LAR(s) of the
             subject prior to enrolment in the study. In addition, subjects below the legal age of
             consent should sign and personally date a written informed assent form

          -  Healthy subjects

          -  Female subjects of non-childbearing potential may be enrolled in the study

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination, and

               -  has agreed to continue adequate contraception during the entire vaccination
                  period and up to two months after the last study vaccine dose

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  A female planning to become pregnant, likely to become pregnant or planning to
             discontinue contraceptive precautions during the entire vaccination period and up to
             two months after the last study vaccine dose

          -  Previous vaccination against HPV or planned administration of another HPV vaccine
             during the study

          -  Child in care. A child in care is a child who has been placed under the control or
             protection of an agency, organisation, institution or entity by the courts, the
             government or a government body, acting in accordance with powers conferred on them
             by law or regulation. The definition of a child in care does not include a child who
             is adopted or has an appointed legal guardian.

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose. History of allergic disease, suspected
             allergy or reactions likely to be exacerbated by any component of the study vaccines

          -  Cancer or autoimmune disease under treatment

          -  Planned administration/administration of a vaccine/product not foreseen by the study
             protocol within 30 days before each dose of vaccine. Administration of routine
             meningococcal, hepatitis B, hepatitis A, inactivated influenza, diphtheria/tetanus
             and/or diphtheria/tetanus-containing vaccine up to 8 days before each dose of study
             vaccine is allowed. Enrolment will be deferred until the subject is outside of
             specified window

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product

          -  Previous administration of MPL or AS04 adjuvant.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition

          -  Family history of congenital or hereditary immunodeficiency

          -  Major congenital defects or serious chronic illness

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests, which in the opinion of the investigator precludes administration of the study
             vaccine

          -  Acute disease and/or fever at the time of enrolment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schoenau am Koenigssee</city>
        <state>Bayern</state>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolfenbuettel</city>
        <state>Niedersachsen</state>
        <zip>38302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolfsburg</city>
        <state>Niedersachsen</state>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kleve-Materborn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weimar</city>
        <state>Thueringen</state>
        <zip>99423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuneo</city>
        <state>Piemonte</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ragusa</city>
        <state>Sicilia</state>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiangmai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>September 10, 2015</lastchanged_date>
  <firstreceived_date>June 17, 2011</firstreceived_date>
  <firstreceived_results_date>June 28, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>HPV-18</keyword>
  <keyword>HPV infection</keyword>
  <keyword>vaccine</keyword>
  <keyword>HPV-16</keyword>
  <keyword>Human Papillomavirus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cervarix 1 Group</title>
          <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Cervarix 2 Group</title>
          <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Cervarix 3 Group</title>
          <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
                <participants group_id="P2" count="482"/>
                <participants group_id="P3" count="415"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="548"/>
                <participants group_id="P2" count="472"/>
                <participants group_id="P3" count="408"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix 1 Group</title>
          <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Cervarix 2 Group</title>
          <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Cervarix 3 Group</title>
          <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="550"/>
                <measurement group_id="B2" value="482"/>
                <measurement group_id="B3" value="415"/>
                <measurement group_id="B4" value="1447"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11.6" spread="1.59"/>
                <measurement group_id="B2" value="19.6" spread="3.05"/>
                <measurement group_id="B3" value="11.4" spread="1.55"/>
                <measurement group_id="B4" value="13.83" spread="4.22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="550"/>
                <measurement group_id="B2" value="482"/>
                <measurement group_id="B3" value="415"/>
                <measurement group_id="B4" value="1447"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti- Human Papilloma Virus 16 (Anti-HPV-16) and Anti-Human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
        <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 ELISA units per millilitre (EL.U/mL) and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL.</description>
        <time_frame>1 month after the last dose of study vaccine (Month 7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="493"/>
                  <measurement group_id="O2" value="382"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for Anti- Human Papilloma Virus 16 (Anti-HPV-16) and Anti-Human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
            <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 ELISA units per millilitre (EL.U/mL) and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [N= 488, 352]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="488"/>
                  <measurement group_id="O2" value="352"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [N=493, 382]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="493"/>
                  <measurement group_id="O2" value="382"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</title>
        <description>Antibody concentrations were and expressed as geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay [ELISA] units per millilitre (EL.U/mL), with the cut-off values of 8 EL.U/mL for HPV-016 and 7 EL.U/mL for HPV-018.</description>
        <time_frame>1 month after the last dose of study vaccine (Month 7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="540"/>
                  <measurement group_id="O2" value="432"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</title>
            <description>Antibody concentrations were and expressed as geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay [ELISA] units per millilitre (EL.U/mL), with the cut-off values of 8 EL.U/mL for HPV-016 and 7 EL.U/mL for HPV-018.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [N= 540, 432]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9413.3" lower_limit="8853.4" upper_limit="10008.7"/>
                  <measurement group_id="O2" value="9970.7" lower_limit="9128.3" upper_limit="10890.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [N=536, 432]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5968.8" lower_limit="5580.3" upper_limit="6384.3"/>
                  <measurement group_id="O2" value="4880.3" lower_limit="4486.4" upper_limit="5308.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 EL.U/mL and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL.
Note: Results for Months 18, 24 and 36 will be updated when they become available.</description>
        <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="493"/>
                  <measurement group_id="O2" value="382"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 EL.U/mL and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL.
Note: Results for Months 18, 24 and 36 will be updated when they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, Day 0 [N= 488, 352]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 7 [N= 488, 352]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="488"/>
                  <measurement group_id="O2" value="352"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 12 [N= 480, 347]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="480"/>
                  <measurement group_id="O2" value="347"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Day 0 [N= 493, 382]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 7 [N= 493, 382]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="493"/>
                  <measurement group_id="O2" value="382"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 12 [N= 485, 376]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="485"/>
                  <measurement group_id="O2" value="376"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 EL.U/mL and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL. Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
        <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="369"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Seroconversion was defined as the appearance of antibodies (anti-HPV-16 titres ≥ 8 EL.U/mL and anti-HPV-18 titres ≥ 7 EL.U/mL) in the serum of subjects seronegative before vaccination. A seronegative subject was a subject with anti-HPV-16/18 antibody concentration &lt; 8/7 EL.U/mL. A seropositive subject was a subject with anti-HPV-16/18 antibody concentration ≥ 8/7 EL.U/mL. Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="355"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="369"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16 and Anti-HPV-18 Antibody Titres (by Pseudovirion-Based Neutralisation Assay [PBNA])</title>
        <description>Antibody titers were given as Geometric mean titers (GMTs). The cut-off of the assay were ≥ 40 ED50 for anti-HPV-16 and anti-HPV-18.
Note: Results for Months 24 and 36 will be updated when they become available.</description>
        <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HPV-16 and Anti-HPV-18 Antibody Titres (by Pseudovirion-Based Neutralisation Assay [PBNA])</title>
            <description>Antibody titers were given as Geometric mean titers (GMTs). The cut-off of the assay were ≥ 40 ED50 for anti-HPV-16 and anti-HPV-18.
Note: Results for Months 24 and 36 will be updated when they become available.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, Day 0 [N=103, 99]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.2" lower_limit="18.9" upper_limit="23.9"/>
                  <measurement group_id="O2" value="23.2" lower_limit="20.7" upper_limit="26.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 7 [N=103, 99]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77611.5" lower_limit="63321.3" upper_limit="95126.5"/>
                  <measurement group_id="O2" value="30254.7" lower_limit="23616.3" upper_limit="38759.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 12 [N=101, 98]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14540.1" lower_limit="11855.1" upper_limit="17833.2"/>
                  <measurement group_id="O2" value="15273.8" lower_limit="11814.3" upper_limit="19746.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Day 0 [N=103, 99]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.0" lower_limit="19.0" upper_limit="23.3"/>
                  <measurement group_id="O2" value="22.2" lower_limit="20.4" upper_limit="24.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 7 [N=103, 92]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23276.4" lower_limit="19557.5" upper_limit="27702.6"/>
                  <measurement group_id="O2" value="13709.2" lower_limit="10863.6" upper_limit="17300.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 12 [N=101, 98]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5703.4" lower_limit="4609.6" upper_limit="7056.8"/>
                  <measurement group_id="O2" value="5083.3" lower_limit="3834.2" upper_limit="6739.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</title>
        <description>Antibody concentrations were expressed as geometric mean titers (GMTs) and given in EL.U/mL, with the cut-off values of ≥ 8 ELISA units per millilitre (EL.U/mL) for HPV-016 and ≥ 7 EL.U/mL for HPV-018Note: Results for Months 18, 24 and 36 will be updated when they become available.</description>
        <time_frame>At Day 0 and Months 7, 12, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="540"/>
                  <measurement group_id="O2" value="432"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</title>
            <description>Antibody concentrations were expressed as geometric mean titers (GMTs) and given in EL.U/mL, with the cut-off values of ≥ 8 ELISA units per millilitre (EL.U/mL) for HPV-016 and ≥ 7 EL.U/mL for HPV-018Note: Results for Months 18, 24 and 36 will be updated when they become available.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, Day 0 [N=540,432]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.7" lower_limit="4.5" upper_limit="5.0"/>
                  <measurement group_id="O2" value="6.1" lower_limit="5.6" upper_limit="6.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 7 [N=540,432]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9413.3" lower_limit="8853.4" upper_limit="10008.7"/>
                  <measurement group_id="O2" value="9970.7" lower_limit="9128.3" upper_limit="10890.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 12 [N=532,425]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2680.3" lower_limit="2510.7" upper_limit="2861.3"/>
                  <measurement group_id="O2" value="3377.7" lower_limit="3077.0" upper_limit="3707.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Day 0 [N=536,432]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.9" lower_limit="3.8" upper_limit="4.1"/>
                  <measurement group_id="O2" value="4.4" lower_limit="4.1" upper_limit="4.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 7 [N=536,432]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5968.8" lower_limit="5580.3" upper_limit="6384.3"/>
                  <measurement group_id="O2" value="4880.3" lower_limit="4486.4" upper_limit="5308.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 12 [N=528,425]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1559.9" lower_limit="1446.8" upper_limit="1681.8"/>
                  <measurement group_id="O2" value="1500.7" lower_limit="1361.3" upper_limit="1654.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</title>
        <description>Antibody concentrations were expressed as geometric mean titers (GMTs) and given in EL.U/mL, with the cut-off values of ≥ 8 ELISA units per millilitre (EL.U/mL) for HPV-16 and ≥ 7 EL.U/mL for HPV-18.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
        <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="394"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).</title>
            <description>Antibody concentrations were expressed as geometric mean titers (GMTs) and given in EL.U/mL, with the cut-off values of ≥ 8 ELISA units per millilitre (EL.U/mL) for HPV-16 and ≥ 7 EL.U/mL for HPV-18.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, Month 0 [N=394]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.6" lower_limit="4.4" upper_limit="4.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 13 [N=394]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11290.0" lower_limit="10520.9" upper_limit="12115.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 0 [N=390]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8" lower_limit="3.7" upper_limit="3.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 13 [N=390]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6601.0" lower_limit="6116.3" upper_limit="7124.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. Any = Occurrence of any solicited local symptom regardless of their intensity grade. Grade 3 pain = Significant pain at rest, that prevented normal every day activity. Grade 3 redness/swelling = Redness/swelling above 50 millimeters (mm).</description>
        <time_frame>During the 7-day period (Days 0-6) following any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="480"/>
                  <measurement group_id="O3" value="413"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
            <description>Assessed solicited local symptoms were pain, redness and swelling. Any = Occurrence of any solicited local symptom regardless of their intensity grade. Grade 3 pain = Significant pain at rest, that prevented normal every day activity. Grade 3 redness/swelling = Redness/swelling above 50 millimeters (mm).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="499"/>
                  <measurement group_id="O2" value="461"/>
                  <measurement group_id="O3" value="381"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="53"/>
                  <measurement group_id="O3" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="247"/>
                  <measurement group_id="O2" value="212"/>
                  <measurement group_id="O3" value="197"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="225"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="171"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, fever and urticaria. Any = Occurrence of any solicited general symptom regardless of intensity grade or relationship to vaccination. Any Fever = Axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C). Grade 3 symptom = Symptom that prevented normal activity. Grade 3 fever = Fever &gt; 39.0 °C. Related = General symptom assessed by the investigator as causally related to the vaccination.</description>
        <time_frame>During the 7-day period (Days 0-6) following any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="480"/>
                  <measurement group_id="O3" value="413"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
            <description>Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, fever and urticaria. Any = Occurrence of any solicited general symptom regardless of intensity grade or relationship to vaccination. Any Fever = Axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C). Grade 3 symptom = Symptom that prevented normal activity. Grade 3 fever = Fever &gt; 39.0 °C. Related = General symptom assessed by the investigator as causally related to the vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Artharlgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="111"/>
                  <measurement group_id="O2" value="107"/>
                  <measurement group_id="O3" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="102"/>
                  <measurement group_id="O3" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="247"/>
                  <measurement group_id="O2" value="310"/>
                  <measurement group_id="O3" value="215"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                  <measurement group_id="O2" value="294"/>
                  <measurement group_id="O3" value="185"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="134"/>
                  <measurement group_id="O3" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="106"/>
                  <measurement group_id="O3" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="246"/>
                  <measurement group_id="O3" value="185"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176"/>
                  <measurement group_id="O2" value="219"/>
                  <measurement group_id="O3" value="148"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="278"/>
                  <measurement group_id="O2" value="295"/>
                  <measurement group_id="O3" value="221"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="265"/>
                  <measurement group_id="O2" value="285"/>
                  <measurement group_id="O3" value="201"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="48"/>
                  <measurement group_id="O3" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 = Unsolicited AE preventing normal activity. Related = Unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the 30-day (Days 0-29) post vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="482"/>
                  <measurement group_id="O3" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
            <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 = Unsolicited AE preventing normal activity. Related = Unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any unsolicited AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="165"/>
                  <measurement group_id="O3" value="74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 unsolicited AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related unsolicited AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)</title>
        <description>pIMDs are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Note: Results up to Months 24 and 36 will be updated once they become available.</description>
        <time_frame>From Day 0 up to Months 7, 13, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="482"/>
                  <measurement group_id="O3" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)</title>
            <description>pIMDs are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Note: Results up to Months 24 and 36 will be updated once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any pIMDs, up to Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="NA">pIMDs were not assessed at Month 7 for this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any pIMDs, up to Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any pIMDs, up to Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically Significant Conditions (MSCs)</title>
        <description>MSC include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.
Note: Results up to Months 24 and 36 will be updated once they become available.</description>
        <time_frame>From Day 0 to Months 7, 13, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="482"/>
                  <measurement group_id="O3" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Medically Significant Conditions (MSCs)</title>
            <description>MSC include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.
Note: Results up to Months 24 and 36 will be updated once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any MSCs, up to Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="96"/>
                  <measurement group_id="O3" value="NA">Results for this group were only available after the last vaccination at Month 12.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any MSCs, up to Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="124"/>
                  <measurement group_id="O3" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any MSCs, up to Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="138"/>
                  <measurement group_id="O3" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pregnancies Ongoing and Their Outcome</title>
        <description>Specific pregnancy outcomes were elective termination with apparent congenital anomaly and ectopic pregnancy. Note: Results for the subsequent timepoints up to Month 36 will be updated once they become available.</description>
        <time_frame>From Day 0 up to Months 7, 13, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on pregnant subjects from the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Pregnancies Ongoing and Their Outcome</title>
            <description>Specific pregnancy outcomes were elective termination with apparent congenital anomaly and ectopic pregnancy. Note: Results for the subsequent timepoints up to Month 36 will be updated once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pregnancy ongoing, Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="NA">For this group, pregnancies and their outcomes were only assessed after the last vaccine dose at Month 12.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination no congenit. anomaly, Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="NA">For this group, pregnancies and their outcomes were only assessed after the last vaccine dose at Month 12.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ectopic pregnancy, Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="NA">For this group, pregnancies and their outcomes were only assessed after the last vaccine dose at Month 12.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ectopic pregnancy, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination no congenit.anomaly, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Live infant no congenital anomaly, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pregnancy ongoing, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stillbirth no congenital anomaly, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ectopic pregnancy, Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination no congenit.anomaly, Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Live infant no congenit. anomaly, Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pregnancy ongoing, Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stillbirth no congenit. anomaly, Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ectopic pregnancy, Month 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination no congenit.anomaly, Month 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Live infant no congenit. anomaly, Month 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pregnancy ongoing, Month 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stillbirth no congenit. anomaly, Month 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Note: Results up to Month 36 will be updated once they become available.</description>
        <time_frame>From Day 0 up to Months 7, 13, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="482"/>
                  <measurement group_id="O3" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
            <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Note: Results up to Month 36 will be updated once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAEs, up to Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="NA">SAEs for this group were only assessed after the last vaccination at Month 12.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs, up to Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="NA">SAEs for this group were only assessed after the last vaccination at Month 12</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any SAEs, up to Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs, up to Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any SAEs, up to Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs, up to Month 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any SAEs, up to Month 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs, up to Month 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific T Cell-mediated Immune Response (CMI)</title>
        <description>The CMI response was the measure of the cytokines production [IL-2, IFN-γ, TNF-α and CD40L] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-18. The frequency was presented as number of cytokine-producing CD4+/CD8+ cells per million CD4+/CD8+ cells.
All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titer lower than the cut-off value of 7 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titer ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
        <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific T Cell-mediated Immune Response (CMI)</title>
            <description>The CMI response was the measure of the cytokines production [IL-2, IFN-γ, TNF-α and CD40L] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-18. The frequency was presented as number of cytokine-producing CD4+/CD8+ cells per million CD4+/CD8+ cells.
All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titer lower than the cut-off value of 7 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titer ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
            <units>cells/million T cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88.0" lower_limit="58.0" upper_limit="129.0"/>
                  <measurement group_id="O2" value="109.5" lower_limit="75.0" upper_limit="175.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S-, Month 7[N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2629.0" lower_limit="1606.0" upper_limit="4256.0"/>
                  <measurement group_id="O2" value="1875.5" lower_limit="1147.0" upper_limit="2565.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112.5" lower_limit="66.5" upper_limit="213.0"/>
                  <measurement group_id="O2" value="128.0" lower_limit="61.5" upper_limit="183.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S+, Month 7[N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1839.0" lower_limit="828.0" upper_limit="3433.0"/>
                  <measurement group_id="O2" value="1286.0" lower_limit="667.0" upper_limit="2504.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59.0" lower_limit="35.0" upper_limit="105.0"/>
                  <measurement group_id="O2" value="87.5" lower_limit="56.0" upper_limit="420.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S-, Month 7 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2408.00" lower_limit="1331.0" upper_limit="3721.0"/>
                  <measurement group_id="O2" value="1709.5" lower_limit="949.0" upper_limit="2324.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="102.0" lower_limit="47.5" upper_limit="203.0"/>
                  <measurement group_id="O2" value="110.5" lower_limit="39.5" upper_limit="169.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S+, Month 7 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1719.5" lower_limit="750.5" upper_limit="3203.5"/>
                  <measurement group_id="O2" value="1232.0" lower_limit="614.0" upper_limit="2211.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.0" lower_limit="19.0" upper_limit="55.0"/>
                  <measurement group_id="O2" value="33.5" lower_limit="19.0" upper_limit="70.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S-, Month 7 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="558.0" lower_limit="220.0" upper_limit="952.0"/>
                  <measurement group_id="O2" value="362.5" lower_limit="192.0" upper_limit="554.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.5" lower_limit="13.0" upper_limit="69.0"/>
                  <measurement group_id="O2" value="28.0" lower_limit="19.0" upper_limit="51.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S+, Month 7 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="523.0" lower_limit="188.0" upper_limit="963.5"/>
                  <measurement group_id="O2" value="312.0" lower_limit="191.0" upper_limit="533.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58.0" lower_limit="22.0" upper_limit="96.0"/>
                  <measurement group_id="O2" value="73.0" lower_limit="41.0" upper_limit="125.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S-, Month 7 [N=69,58</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2465.0" lower_limit="1452.0" upper_limit="3904.0"/>
                  <measurement group_id="O2" value="1760.0" lower_limit="1026.0" upper_limit="2329.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.0" lower_limit="34.5" upper_limit="129.0"/>
                  <measurement group_id="O2" value="96.5" lower_limit="46.5" upper_limit="140.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S+, Month 7 [N=12,13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1704.0" lower_limit="763.5" upper_limit="3223.0"/>
                  <measurement group_id="O2" value="1220.0" lower_limit="572.0" upper_limit="2282.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53.0" lower_limit="30.0" upper_limit="72.0"/>
                  <measurement group_id="O2" value="73.0" lower_limit="29.0" upper_limit="127.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S-, Month 7 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1602.0" lower_limit="979.0" upper_limit="2822.0"/>
                  <measurement group_id="O2" value="1384.0" lower_limit="824.0" upper_limit="2030.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.0" lower_limit="44.5" upper_limit="150.5"/>
                  <measurement group_id="O2" value="68.0" lower_limit="32.5" upper_limit="123.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S+, Month 7 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1362.0" lower_limit="516.5" upper_limit="2634.5"/>
                  <measurement group_id="O2" value="945.0" lower_limit="498.0" upper_limit="2050.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="36.0"/>
                  <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="33.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S-, Month 7[N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="37.0"/>
                  <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="32.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="19.0"/>
                  <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="34.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S+, Month 7[N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="61.5"/>
                  <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="73.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S-, Month 7 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S+, Month 7 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="29.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="24.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S-, Month 7 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="26.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="9.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="15.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="30.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S+, Month 7 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="57.5"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="39.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S-, Month 7 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="22.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S+, Month 7 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="15.5"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S-, Day 0 [N=83,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="12.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="8.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S-, Month 7 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="30.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="27.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S+, Day 0 [N=12,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="15.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="30.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S+, Month 7 [N=12,14]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="57.5"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="62.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2007.0" lower_limit="1053.0" upper_limit="3437.0"/>
                  <measurement group_id="O2" value="1269.0" lower_limit="816.0" upper_limit="2360.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="890.0" lower_limit="576.0" upper_limit="2069.0"/>
                  <measurement group_id="O2" value="764.0" lower_limit="424.0" upper_limit="1771.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1956.0" lower_limit="1019.0" upper_limit="3206.0"/>
                  <measurement group_id="O2" value="1208.0" lower_limit="808.0" upper_limit="2321.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="850.0" lower_limit="572.0" upper_limit="2008.0"/>
                  <measurement group_id="O2" value="752.0" lower_limit="402.0" upper_limit="1724.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="340.0" lower_limit="132.0" upper_limit="640.0"/>
                  <measurement group_id="O2" value="225.0" lower_limit="115.0" upper_limit="407.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="239.0" lower_limit="102.0" upper_limit="535.0"/>
                  <measurement group_id="O2" value="153.5" lower_limit="85.0" upper_limit="344.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S-, Mth 12 [N=69,58</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1839.0" lower_limit="1009.0" upper_limit="3262.0"/>
                  <measurement group_id="O2" value="1195.0" lower_limit="756.0" upper_limit="2177.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="868.0" lower_limit="556.0" upper_limit="2022.0"/>
                  <measurement group_id="O2" value="744.5" lower_limit="318.0" upper_limit="1650.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1569.0" lower_limit="715.0" upper_limit="2608.0"/>
                  <measurement group_id="O2" value="1010.0" lower_limit="603.0" upper_limit="1707.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S+, Mth 12 [N=12,14]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="635.0" lower_limit="391.0" upper_limit="1696.0"/>
                  <measurement group_id="O2" value="632.0" lower_limit="372.0" upper_limit="1284.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8 all doubles, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.0" lower_limit="11.0" upper_limit="46.0"/>
                  <measurement group_id="O2" value="33.0" lower_limit="11.0" upper_limit="50.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8 all doubles, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47.0" lower_limit="11.0" upper_limit="73.0"/>
                  <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="44.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="32.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="36.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.0" lower_limit="7.0" upper_limit="48.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="32.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="38.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.0" lower_limit="7.0" upper_limit="57.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="36.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S-, Mth 12 [N=69,58</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="25.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S+, Mth 12 [N=12,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="25.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="23.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S-, Mth 12 [N=69,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="31.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="35.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S+, Mth 12 [N=12,14]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="55.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="15.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific T Cell-mediated Immune Response (CMI)</title>
        <description>The CMI response was the measure of the cytokines production [i.e.interleukin-2 (IL-2), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and cluster of differentiation 40 Ligand (CD40L)] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-16 The frequency was presented as number of of cytokine-positive cluster of differentiation (CD)4 i.e.CD4+/CD8+ cells per million CD4+/CD8+ cells.
All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 8 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 8 El.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
        <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific T Cell-mediated Immune Response (CMI)</title>
            <description>The CMI response was the measure of the cytokines production [i.e.interleukin-2 (IL-2), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and cluster of differentiation 40 Ligand (CD40L)] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-16 The frequency was presented as number of of cytokine-positive cluster of differentiation (CD)4 i.e.CD4+/CD8+ cells per million CD4+/CD8+ cells.
All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 8 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 8 El.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
            <units>cells/million T cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88.0" lower_limit="56.0" upper_limit="152.0"/>
                  <measurement group_id="O2" value="123.0" lower_limit="67.0" upper_limit="185.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S-, Month 7[N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3935.5" lower_limit="1838.5" upper_limit="6975.5"/>
                  <measurement group_id="O2" value="3691.0" lower_limit="1889.0" upper_limit="5214.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.0" lower_limit="57.0" upper_limit="189.0"/>
                  <measurement group_id="O2" value="87.0" lower_limit="60.0" upper_limit="193.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S+, Month 7[N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4982.5" lower_limit="1584.0" upper_limit="6610.0"/>
                  <measurement group_id="O2" value="1672.0" lower_limit="1233.5" upper_limit="2600.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67.5" lower_limit="42.0" upper_limit="130.0"/>
                  <measurement group_id="O2" value="97.0" lower_limit="52.5" upper_limit="131.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S-, Month 7 [N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3529.5" lower_limit="1673.0" upper_limit="6384.0"/>
                  <measurement group_id="O2" value="3392.0" lower_limit="1692.0" upper_limit="4760.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.0" lower_limit="38.0" upper_limit="161.0"/>
                  <measurement group_id="O2" value="61.0" lower_limit="40.0" upper_limit="164.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4852.0" lower_limit="1490.0" upper_limit="6368.0"/>
                  <measurement group_id="O2" value="1581.5" lower_limit="1087.0" upper_limit="2193.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.0" lower_limit="19.0" upper_limit="67.0"/>
                  <measurement group_id="O2" value="43.5" lower_limit="20.0" upper_limit="73.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S-, Month 7 [N=74,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="823.5" lower_limit="475.0" upper_limit="1488.0"/>
                  <measurement group_id="O2" value="684.0" lower_limit="474.0" upper_limit="1185.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.0" lower_limit="22.0" upper_limit="51.0"/>
                  <measurement group_id="O2" value="49.0" lower_limit="30.0" upper_limit="58.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="778.0" lower_limit="425.0" upper_limit="2351.0"/>
                  <measurement group_id="O2" value="408.5" lower_limit="270.0" upper_limit="863.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58.5" lower_limit="33.0" upper_limit="98.0"/>
                  <measurement group_id="O2" value="86.5" lower_limit="43.5" upper_limit="135.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S-, Month 7 [N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3794.0" lower_limit="1709.0" upper_limit="6736.5"/>
                  <measurement group_id="O2" value="3347.0" lower_limit="1788.0" upper_limit="5010.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53.0" lower_limit="24.0" upper_limit="147.0"/>
                  <measurement group_id="O2" value="72.0" lower_limit="39.0" upper_limit="151.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4807.5" lower_limit="1450.0" upper_limit="6164.0"/>
                  <measurement group_id="O2" value="1549.0" lower_limit="1145.0" upper_limit="2436.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S-, Day 0 [N=86,72]]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58.0" lower_limit="35.0" upper_limit="93.0"/>
                  <measurement group_id="O2" value="68.0" lower_limit="31.0" upper_limit="118.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S-, Month 7 [N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2431.5" lower_limit="1238.0" upper_limit="4743.5"/>
                  <measurement group_id="O2" value="2713.5" lower_limit="1224.0" upper_limit="3675.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47.0" lower_limit="35.0" upper_limit="113.0"/>
                  <measurement group_id="O2" value="59.0" lower_limit="49.0" upper_limit="84.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2128.5" lower_limit="1353.0" upper_limit="3523.0"/>
                  <measurement group_id="O2" value="1185.0" lower_limit="838.0" upper_limit="1913.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="41.0"/>
                  <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="44.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S-, Month 7[N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="41.0"/>
                  <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="37.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="58.0"/>
                  <measurement group_id="O2" value="36.0" lower_limit="26.0" upper_limit="43.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S+, Month 7[N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="11.0"/>
                  <measurement group_id="O2" value="33.5" lower_limit="11.0" upper_limit="43.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S-, Month 7 [N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="22.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="32.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="37.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S-, Month 7 [N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="34.5"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="27.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="54.0"/>
                  <measurement group_id="O2" value="32.0" lower_limit="22.0" upper_limit="39.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="22.0" lower_limit="7.0" upper_limit="35.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S-, Month 7 [N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="38.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S-, Day 0 [N=86,72]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="29.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="28.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S-, Month 7 [N=72,54]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="33.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="32.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S+, Day 0 [N=10,17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="54.0"/>
                  <measurement group_id="O2" value="22.0" lower_limit="7.0" upper_limit="32.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S+, Month 7 [N=10,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="25.0" lower_limit="7.0" upper_limit="38.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2510.0" lower_limit="1374.0" upper_limit="5495.0"/>
                  <measurement group_id="O2" value="2360.5" lower_limit="1234.0" upper_limit="3463.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3317.0" lower_limit="1003.0" upper_limit="3428.0"/>
                  <measurement group_id="O2" value="1344.5" lower_limit="874.0" upper_limit="3222.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2465.0" lower_limit="1310.0" upper_limit="5324.0"/>
                  <measurement group_id="O2" value="2316.5" lower_limit="1218.0" upper_limit="3440.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3287.0" lower_limit="975.0" upper_limit="3378.0"/>
                  <measurement group_id="O2" value="1334.5" lower_limit="850.0" upper_limit="3118.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="526.0" lower_limit="181.0" upper_limit="999.0"/>
                  <measurement group_id="O2" value="369.0" lower_limit="207.0" upper_limit="718.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="527.0" lower_limit="162.0" upper_limit="827.0"/>
                  <measurement group_id="O2" value="365.5" lower_limit="199.0" upper_limit="477.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2421.0" lower_limit="1275.0" upper_limit="5181.0"/>
                  <measurement group_id="O2" value="2273.0" lower_limit="1164.0" upper_limit="3242.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3068.0" lower_limit="877.0" upper_limit="3424.0"/>
                  <measurement group_id="O2" value="1236.5" lower_limit="814.5" upper_limit="3166.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1874.0" lower_limit="812.0" upper_limit="4009.0"/>
                  <measurement group_id="O2" value="1743.0" lower_limit="933.0" upper_limit="2521.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2200.0" lower_limit="875.0" upper_limit="2891.0"/>
                  <measurement group_id="O2" value="1126.5" lower_limit="685.0" upper_limit="2382.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8 all doubles, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="41.0"/>
                  <measurement group_id="O2" value="35.0" lower_limit="11.0" upper_limit="50.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8 all doubles, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.0" lower_limit="11.0" upper_limit="105.0"/>
                  <measurement group_id="O2" value="29.0" lower_limit="11.0" upper_limit="57.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="32.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="37.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.0" lower_limit="7.0" upper_limit="53.0"/>
                  <measurement group_id="O2" value="15.0" lower_limit="7.0" upper_limit="36.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="37.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="46.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.0" lower_limit="7.0" upper_limit="73.0"/>
                  <measurement group_id="O2" value="15.0" lower_limit="7.0" upper_limit="38.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="47.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="15.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S-, Mth 12 [N=87,74]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="39.0"/>
                  <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="36.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S+, Mth 12 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.0" lower_limit="7.0" upper_limit="55.0"/>
                  <measurement group_id="O2" value="15.0" lower_limit="7.0" upper_limit="29.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific T Cell-mediated Immune Response (CMI)</title>
        <description>The CMI response was the measure of the cytokines production [i.e.interleukin-2 (IL-2), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and cluster of differentiation 40 Ligand (CD40L)] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-16 The frequency was presented as number of of cytokine-positive cluster of differentiation (CD)4 i.e.CD4+/CD8+ cells per million CD4+/CD8+ cells. All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 8 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 8 El.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
        <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific T Cell-mediated Immune Response (CMI)</title>
            <description>The CMI response was the measure of the cytokines production [i.e.interleukin-2 (IL-2), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and cluster of differentiation 40 Ligand (CD40L)] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-16 The frequency was presented as number of of cytokine-positive cluster of differentiation (CD)4 i.e.CD4+/CD8+ cells per million CD4+/CD8+ cells. All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 8 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 8 El.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
            <units>cells/million T cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96.0" lower_limit="61.0" upper_limit="170.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2399.0" lower_limit="1514.0" upper_limit="4361.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="169.0" lower_limit="77.0" upper_limit="277.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4 all doubles, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2507.5" lower_limit="1067.0" upper_limit="4212.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89.0" lower_limit="47.0" upper_limit="133.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2356.0" lower_limit="1510.0" upper_limit="4322.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="141.0" lower_limit="73.0" upper_limit="261.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-CD40L, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2450.5" lower_limit="1036.0" upper_limit="4139.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.0" lower_limit="20.0" upper_limit="60.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="661.0" lower_limit="292.0" upper_limit="1452.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.0" lower_limit="33.0" upper_limit="203.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IFNγ, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="644.0" lower_limit="204.0" upper_limit="1163.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63.0" lower_limit="34.0" upper_limit="112.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2220.0" lower_limit="1406.0" upper_limit="4128.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="121.0" lower_limit="47.0" upper_limit="191.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-IL-2, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2442.0" lower_limit="835.0" upper_limit="4006.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63.0" lower_limit="36.0" upper_limit="102.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1643.0" lower_limit="907.0" upper_limit="3076.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140.0" lower_limit="32.0" upper_limit="164.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD4-d-TNFα, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1843.0" lower_limit="584.0" upper_limit="2657.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.0" lower_limit="11.0" upper_limit="55.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="43.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.0" lower_limit="11.0" upper_limit="59.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-all doubles, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.0" lower_limit="11.0" upper_limit="57.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="35.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="30.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="35.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-CD40L, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="34.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.0" lower_limit="7.0" upper_limit="48.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="35.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.0" lower_limit="7.0" upper_limit="55.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IFNγ, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.5" lower_limit="7.0" upper_limit="53.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-IL-2, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="27.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="29.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, CD8-d-TNFα, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.5" lower_limit="7.0" upper_limit="44.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific T Cell-mediated Immune Response (CMI)</title>
        <description>The CMI response was the measure of the cytokines production [IL-2, IFN-γ, TNF-α and CD40L] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-18. The frequency was presented as number of cytokine-producing CD4+/CD8+ cells per million CD4+/CD8+ cells. All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 7 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
        <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific T Cell-mediated Immune Response (CMI)</title>
            <description>The CMI response was the measure of the cytokines production [IL-2, IFN-γ, TNF-α and CD40L] by HPV-antigen specific T lymphocytes and measured by intracellular cytokine staining (ICS) assay for HPV-18. The frequency was presented as number of cytokine-producing CD4+/CD8+ cells per million CD4+/CD8+ cells. All doubles= T cell expressing at least 2 cytokines. Results were tabulated by the pre-vaccination status of the subjects, where S- = seronegative subjects (antibody titre lower than the cut-off value of 7 EL.U/mL) prior to vaccination. S+ = seropositive subjects (antibody titre ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
            <units>cells/million T-cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.0" lower_limit="60.0" upper_limit="147.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1582.0" lower_limit="1033.0" upper_limit="3107.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107.5" lower_limit="69.0" upper_limit="146.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4 all doubles, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1968.5" lower_limit="1753.0" upper_limit="2184.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85.0" lower_limit="41.5" upper_limit="126.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1529.0" lower_limit="1003.0" upper_limit="3036.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103.5" lower_limit="65.0" upper_limit="142.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-CD40L, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1904.5" lower_limit="1656.0" upper_limit="2153.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.0" lower_limit="27.0" upper_limit="61.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="349.0" lower_limit="173.0" upper_limit="1221.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.5" lower_limit="24.0" upper_limit="43.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IFNγ, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="378.0" lower_limit="307.0" upper_limit="449.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60" lower_limit="32.0" upper_limit="97.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1452.0" lower_limit="812.0" upper_limit="2851.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.5" lower_limit="33.0" upper_limit="60.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-IL-2, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1845.0" lower_limit="1544.0" upper_limit="2146.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.0" lower_limit="34.0" upper_limit="97.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1126.0" lower_limit="649.0" upper_limit="2076.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.5" lower_limit="29.0" upper_limit="104.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD4-d-TNFα, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1449.5" lower_limit="1317.0" upper_limit="1582.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.0" lower_limit="11.0" upper_limit="47.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.0" lower_limit="11.0" upper_limit="53.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.0" lower_limit="11.0" upper_limit="47.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-all doubles, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63.5" lower_limit="39.0" upper_limit="88.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="31.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="38.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.0" lower_limit="7.0" upper_limit="43.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-CD40L, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.0" lower_limit="7.0" upper_limit="35.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="41.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="44.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.0" lower_limit="7.0" upper_limit="43.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IFNγ, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59.5" lower_limit="35.0" upper_limit="84.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="19.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-IL-2, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.5" lower_limit="7.0" upper_limit="84.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="38.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="31.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, CD8-d-TNFα, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific B Cell-mediated Immune Response</title>
        <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-16 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 8 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 8 EL.U/mL) prior to vaccination.
Note:Results for Months 24 and 36 will be updated once they become available.</description>
        <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific B Cell-mediated Immune Response</title>
            <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-16 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 8 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 8 EL.U/mL) prior to vaccination.
Note:Results for Months 24 and 36 will be updated once they become available.</description>
            <units>cells/million B-cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, S-, Day 0 [N=79, 69]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S-, Month 7 [N=75, 55]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2210.0" lower_limit="886.0" upper_limit="5171.0"/>
                  <measurement group_id="O2" value="1692.0" lower_limit="849.0" upper_limit="3449.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S-, Month 12 [N=59, 43]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="801.0" lower_limit="437.0" upper_limit="2553.0"/>
                  <measurement group_id="O2" value="1136.0" lower_limit="371.0" upper_limit="3215.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S+, Day 0 [N=10, 17]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  <measurement group_id="O2" value="16.0" lower_limit="1.0" upper_limit="58.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S+, Month 7 [N=9, 15]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4467.0" lower_limit="1513.0" upper_limit="8673.0"/>
                  <measurement group_id="O2" value="1354.0" lower_limit="197.0" upper_limit="4928.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S+, Month 12 [N=3, 10]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5018.0" lower_limit="1064.0" upper_limit="5094.0"/>
                  <measurement group_id="O2" value="785.0" lower_limit="340.0" upper_limit="2517.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific B Cell-mediated Immune Response</title>
        <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-18 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 7 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
        <time_frame>At Day 0 and Months 7, 12, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination and B-cell pre-vaccination status.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific B Cell-mediated Immune Response</title>
            <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-18 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 7 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 24 and 36 will be updated once they become available.</description>
            <units>cells/million B-cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-18, S-, Day 0 [N=78,71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, S-, Month 7 [N=73,58]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="935.0" lower_limit="407.0" upper_limit="2485.0"/>
                  <measurement group_id="O2" value="838.0" lower_limit="430.0" upper_limit="2062.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, S+, Day 0 [N=11,16]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="85.0"/>
                  <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="11.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, S+, Month 7 [N=11,13]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2175.0" lower_limit="423.0" upper_limit="3414.0"/>
                  <measurement group_id="O2" value="755.0" lower_limit="180.0" upper_limit="2505.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific B Cell-mediated Immune Response</title>
        <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-16 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 8 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 8 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
        <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-16 Specific B Cell-mediated Immune Response</title>
            <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-16 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 8 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 8 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
            <units>cells/million T-cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2825.0" lower_limit="1429.5" upper_limit="5421.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="20.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5996.0" lower_limit="919.0" upper_limit="7353.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific B Cell-mediated Immune Response</title>
        <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-18 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 7 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
        <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cell-mediated Immunogenicity Related to Anti-HPV-18 Specific B Cell-mediated Immune Response</title>
            <description>The cell-mediated immune response was assessed as being the frequency of B-cell memory of HPV-18 antigen-specific memory B-cells per million memory B-cells in subjects with detectable B-cells. The results are presented by pre-vaccination status, where S- = seronegative subjects (antibody concentration &lt; 7 EL.U/mL) prior to vaccination and S+ = seropositive subjects (antibody concentration ≥ 7 EL.U/mL) prior to vaccination.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
            <units>cells/million B-cells</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-18, S-, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, S-, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1165.0" lower_limit="632.0" upper_limit="1780.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, S+, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.0" lower_limit="48.0" upper_limit="48.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, S+, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="758.0" lower_limit="114.0" upper_limit="1402.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Completing the Vaccination Course</title>
        <description>The number of subjects completing the vaccination course was assessed as the number of subjects with at least one dose received during the study.</description>
        <time_frame>Up to Month 13</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects, i.e. subjects who received at least one dose of vaccine in this study, for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 1 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 2 Group</title>
            <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="482"/>
                  <measurement group_id="O3" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Completing the Vaccination Course</title>
            <description>The number of subjects completing the vaccination course was assessed as the number of subjects with at least one dose received during the study.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="550"/>
                  <measurement group_id="O2" value="482"/>
                  <measurement group_id="O3" value="415"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16 and Anti-HPV-18 Antibody Titres (by Pseudovirion-Based Neutralisation Assay [PBNA])</title>
        <description>Antibody titers were given as Geometric mean titers (GMTs). The cut-off of the assay were ≥ 40 ED50 for anti-HPV-16 and anti-HPV-18.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
        <time_frame>At Months 0, 13, 18, 24 and 36</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 3 Group</title>
            <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HPV-16 and Anti-HPV-18 Antibody Titres (by Pseudovirion-Based Neutralisation Assay [PBNA])</title>
            <description>Antibody titers were given as Geometric mean titers (GMTs). The cut-off of the assay were ≥ 40 ED50 for anti-HPV-16 and anti-HPV-18.
Note: Results for Months 18, 24 and 36 will be updated when they become available. For this group, results were only made available one month after the last vaccine dose, at Month 13.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77202.4" lower_limit="62934.5" upper_limit="94705.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.0" lower_limit="20.0" upper_limit="20.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18, Month 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40052.6" lower_limit="33593.3" upper_limit="47753.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms were collected during the 7-day period (Days 0-6) after vaccination.Unsolicited AEs were collected during the 30-day period (Days 0-29) after vaccination. SAEs were collected from Day 0 to Month 24.</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix 1 Group</title>
          <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Cervarix 2 Group</title>
          <description>Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Cervarix 3 Group</title>
          <description>Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Months 0 and 12. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Medulloblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy termination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="499" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="461" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="381" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="499" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="461" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="381" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="197" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="310" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="215" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="246" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="185" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="295" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="221" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="550"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="482"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
